The estimated Net Worth of Troy Edward Wilson is at least 20.1 百万$ dollars as of 13 June 2024. Troy Wilson owns over 27,000 units of Kura Oncology Inc stock worth over 6,958$ and over the last 11 years he sold KURA stock worth over 16,875,689$. In addition, he makes 3,236,220$ as Chairman of the Board、 President、 Chief Executive Officer at Kura Oncology Inc.
Troy has made over 13 trades of the Kura Oncology Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 27,000 units of KURA stock worth 89,910$ on 13 June 2024.
The largest trade he's ever made was selling 261,692 units of Kura Oncology Inc stock on 6 October 2020 worth over 8,698,642$. On average, Troy trades about 18,566 units every 35 days since 2013. As of 13 June 2024 he still owns at least 350 units of Kura Oncology Inc stock.
You can see the complete history of Troy Wilson stock trades at the bottom of the page.
Dr. Troy E. Wilson Ph.D., J.D. serves as Chairman of the Board, President, Chief Executive Officer of the Company. He has served as our President and Chief Executive Officer and as the chairman of our Board of Directors since March 2015. Dr. Wilson co-founded Kura Oncology in August 2014 and served as the President and Chief Executive Officer as well as a member of the Company’s Board of Directors from August 2014. Dr. Wilson served as President and Chief Executive Officer of Wellspring Biosciences, Inc., a privately-held biopharmaceutical company, and its parent company Araxes Pharma LLC, or Araxes, from July 2012 to March 2019 and as President and Chief Executive Officer of Avidity Biosciences, Inc., a privately-held biopharmaceutical company, from November 2012 to February 2019. Dr. Wilson served as the President and Chief Executive Officer and a member of the Board of Directors of Intellikine, Inc., a privately-held biopharmaceutical company, from April 2007 to January 2012 and from August 2007 to January 2012, respectively, until its acquisition by Takeda Pharmaceutical Company Limited. He has also been a member of the Board of Directors of Puma Biotechnology, Inc., a publicly-held biopharmaceutical company, since October 2013, and a member of the Board of Directors of Zosano Pharma, Inc., a publicly-held biopharmaceutical company, since June 2014. Dr. Wilson holds a J.D. from New York University and graduated with a Ph.D. in bioorganic chemistry and a B.A. in biophysics from the University of California, Berkeley.
As the Chairman of the Board、 President、 Chief Executive Officer of Kura Oncology Inc, the total compensation of Troy Wilson at Kura Oncology Inc is 3,236,220$. There are 1 executives at Kura Oncology Inc getting paid more, with Kathleen Ford having the highest compensation of 3,485,030$.
Troy Wilson is 51, he's been the Chairman of the Board、 President、 Chief Executive Officer of Kura Oncology Inc since 2018. There are 12 older and 8 younger executives at Kura Oncology Inc. The oldest executive at Kura Oncology Inc is Kathleen Ford, 74, who is the Chief Operating Officer.
Troy's mailing address filed with the SEC is C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES, CA, 90024.
Over the last 6 years, insiders at Kura Oncology Inc have traded over 16,903,587$ worth of Kura Oncology Inc stock and bought 50,000 units worth 575,000$ . The most active insiders traders include Faheem Hasnain、Troy Edward Wilson、Mary T Szela. On average, Kura Oncology Inc executives and independent directors trade stock every 63 days with the average trade being worth of 626,260$. The most recent stock trade was executed by Teresa Brophy Bair on 20 May 2024, trading 2,615 units of KURA stock currently worth 57,922$.
at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.
Kura Oncology Inc executives and other stock owners filed with the SEC include: